YK-029A

YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models.


Cat. No.: EX-A8793	Purity: >98%

	Chemical structure of YK-029A

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	950	In-stock
50mg	1350	In-stock
100mg	1950	In-stock
200mg	2850	In-stock
500mg	get quote	In-stock
1g	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2064269-82-3
Purity	>98%
Formula	C27H32N8O2
Mol Weight	500.5954
Color	Off-white to light yellow
State	solid powder
Solubility	DMSO : 100 mg/mL
Shelf Life	>3 years if stored properly
Storage	Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 month
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Liu B, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023 Oct 5;258:115590.
CoA	CoA of YK-029A


		Search